## Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation



Erratum: This corrects the article "Efficacy of formoterol fumarate delivered by metered dose inhaler using Cosuspension™ delivery technology versus Foradil® Aerolizer® in moderate-to-severe COPD: a randomized, doseranging study" in volume 4, Issue 1, page 21-33.

## **Erratum**

 $\textbf{Citation:} \ \texttt{Erratum.} \ \textit{Chronic Obstr Pulm Dis.} \ 2017; 4 (3): 258. \ \textit{doi: https://doi.org/} 10.15326/jcopdf. 4.3. 2016.0158$ 

In Volume 4, Issue 1, published in January 2017, the article, "Efficacy of formoterol fumarate delivered by metered dose inhaler using Co-suspension™ delivery technology versus Foradil® Aerolizer® in moderate-to-severe COPD: a randomized, dose-ranging study" (*Chronic Obstr Pulm Dis.* 2017; 4(1): 21-33. doi: <a href="http://doi.org/10.15326/jcopdf.4.1.2016.0158">http://doi.org/10.15326/jcopdf.4.1.2016.0158</a>) by Sethi et al, contained a mistake in the Methods: Study Patient Population section. The second sentence of this section should have read:

"Patients were also required to have a post-bronchodilator FEV<sub>1</sub>  $\geq$ 30% and <80% of the predicted value **and**  $\geq$ 750mL at screening (Visit 1) and pre-bronchodilator FEV<sub>1</sub> <80% of the predicted value at baseline (Visit 2)."

This correction has been posted in the online version of the article. The authors regret this error.